A closely watched drug for a common heart disease risk factor has failed in its biggest test. Pelacarsen, developed by Novartis, targets Lp(a), a particle made from lipids and proteins whose elevated concentrations in the blood raise the likelihood of serious cardiac events. Novartis said Friday the drug showed no benefit over a placebo in the Phase 3 HORIZON trial, a result the company described as a major blow.
What the trial actually showed
Phase 3 is the final stage of large-scale clinical testing. At that stage, a drug must demonstrate it prevents real health events in patients, a bar that a promising laboratory result alone cannot clear. The HORIZON trial asked whether pelacarsen could cut the rate of cardiovascular death or emergencies such as heart attacks and strokes. Compared to patients given a placebo, it could not.
That gap matters because the earlier data had been genuinely promising. Prior trials showed pelacarsen was capable of drastically lowering Lp(a) levels in the blood, and researchers had grounds to believe that reducing the particle would translate into fewer cardiac events. HORIZON tested that assumption directly. Lowering a blood measurement and preventing an actual cardiac emergency are two separate things, and the trial found no link between them.
Lp(a) as a treatment target
Lp(a) has drawn sustained attention in cardiovascular research for one specific reason: standard cholesterol-lowering drugs, including statins, do little to move it. That left a gap for drug developers working on cardiovascular risk that existing medicines cannot reach, and Novartis moved to fill it by targeting Lp(a) directly.
The company called the HORIZON outcome a major blow to its own program and to broader efforts to establish elevated Lp(a) as a viable target in cardiovascular medicine.